Core Viewpoint - The company, Jemete, has announced an annual performance forecast indicating a projected net loss for 2025, attributed to various factors including changes in client business and international policies [1] Group 1: Financial Performance - The expected net profit attributable to shareholders for 2025 is projected to be a loss between 44 million to 64 million yuan [1] - The expected net profit after deducting non-recurring gains and losses is projected to be a loss between 67 million to 97 million yuan [1] Group 2: Revenue and Profitability Factors - Overall revenue and gross profit are expected to decrease due to changes in client business and international policy impacts [1] - Although revenue from the company's own brand business has increased compared to the previous year, the ODM/OEM business has seen a reduction in order demand from domestic clients due to their own business changes [1] - International clients have shifted supply chains to Southeast Asia due to tariff policy changes and international political situations, leading to a decrease in orders for the company [1] Group 3: Financial Costs - Financial expenses have increased due to fluctuations in the currency market, with exchange losses rising as the company's export business is primarily settled in US dollars [1] - The decline in cash management income is attributed to lower market interest rates compared to the previous year [1] Group 4: Marketing and Promotion Expenses - Sales expenses have increased compared to the previous year, primarily due to the company's intensified efforts in expanding its own brand business [1] - The increase in marketing expenses has contributed to the growth in revenue from the company's own brand business [1]

Core Viewpoint - Jiuan Medical experienced a decline of 2.78% in stock price on November 11, with a trading volume of 1.483 billion yuan, indicating market volatility and investor sentiment towards the company [1]. Financing and Margin Trading - On November 11, Jiuan Medical had a financing buy-in amount of 198 million yuan and a financing repayment of 188 million yuan, resulting in a net financing purchase of 9.05 million yuan [1]. - The total margin trading balance for Jiuan Medical reached 1.242 billion yuan as of November 11, with a financing balance of 1.231 billion yuan, accounting for 6.16% of the circulating market value, which is above the 90th percentile of the past year [1]. - In terms of securities lending, Jiuan Medical repaid 4,600 shares and sold 300 shares on November 11, with a remaining short position of 261,100 shares and a short balance of 11.2173 million yuan, also above the 90th percentile of the past year [1]. Company Overview - Jiuan Medical, established on August 22, 1995, and listed on June 10, 2010, is located in Tianjin and specializes in the research, production, and sales of home medical health electronic products [1]. - The revenue composition of Jiuan Medical includes iHealth series products (78.56%), ODM/OEM products (7.72%), internet medical products and services (6.57%), new retail business (5.03%), traditional hardware products (1.46%), and others (0.66%) [1]. Shareholder and Financial Performance - As of October 31, the number of shareholders for Jiuan Medical was 67,500, a decrease of 3.30% from the previous period, while the average circulating shares per person increased by 3.41% to 6,878 shares [2]. - For the period from January to September 2025, Jiuan Medical reported a revenue of 1.069 billion yuan, a year-on-year decrease of 48.89%, while the net profit attributable to shareholders increased by 16.11% to 158.9 million yuan [2]. Dividend and Institutional Holdings - Jiuan Medical has distributed a total of 1.794 billion yuan in dividends since its A-share listing, with 1.39 billion yuan distributed over the past three years [3]. - As of September 30, 2025, among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF held 9.4265 million shares, a decrease of 1.562 million shares from the previous period, while other institutional shareholders also reported reductions in their holdings [3].